

INFORMATION DISCLOSURE STATEMENT

As a means of complying with the duty of disclosure, Applicant's submit an "Information Disclosure Statement by Applicant" on PTO Form PTO/SB/08A for consideration by the Examiner. Since this statement is being submitted during the period specified in 37 C.F.R. § 1.97(b), no fee is due for this submission.

In accordance with 37 C.F.R. 1.98(d), it is believed that a copy of each cited reference may be found at in the file of the parent application. If this is incorrect, the Examiner is kindly requested to contact the undersigned to request copies.

Applicants would also like to provide the Examiner the following background information:

BACKGROUND INFORMATION

This application claims compounds first disclosed in PCT/GB00/02302, from which the parent of the present application claims priority under 35 U.S.C. § 119.

PCT/GB00/02302 has entered the U.S. national stage as U.S. patent application serial number 09/926,712. The claims in the 09/926,712 application have been amended so as not to read on any of the compounds originally claimed in the present application.

The compounds were invented in the course of a research collaboration between Eli Lilly and Company (the assignee of record) and Protherics Molecular Design Limited (now Tularik Limited, a subsidiary of Tularik Inc).. The

Continuation of Serial No. 10/030,187

predecessor company of Protherics Molecular Design Limited was Proteus Molecular Design Limited.

This application forms part of a portfolio of patent applications directed to serine protease inhibitors, some of which belong to Eli Lilly and Company, and some of which belong to Tularik Limited. The history of this portfolio traces back to a research project on serine protease inhibitors started by Proteus Molecular Design Limited. The undersigned is responsible for handling the applications in this portfolio.

A listing of the co-pending applications and patents in the portfolio is provided on the next page.

Continuation of Serial No. 10/030,187

Co-Pending Lilly and Tularik Applications and Patents

Co-pending applications - Assigned to Eli Lilly and Company

09/926,712 (national stage of WO 00/76971)
09/926,716 (national stage of WO 00/76970 - abandoned)
10/030,188 (national stage of WO 01/96303)
10/030,186 (national stage of WO 01/96304)
10/030,189 (national stage of WO 01/96296)
10/477,192 (national stage of WO 02/100847)

Co-pending applications and patents - Assigned to Tularik Limited

US 6262069 and US 6420438 (national stage of WO 99/11657 and continuation)
09/988,082 (continuation-in-part of 09/485,678, WO 99/11658 and of WO 00/77027)
10/148,174 (national stage of WO 01/44226)
10/296,245 (national stage of WO 01/96305)
10/432,365 (national stage of WO 02/47762)

COMMUNICATION BY TELEPHONE

The undersigned's office is located in the United Kingdom, and hence the Examiner may have difficulty contacting him from the USPTO by telephone. If the Examiner wishes to speak with the undersigned by telephone, he can contact the undersigned by e-mail at martinahay@martin-a-hay.com, or leave a message with Linda McDonald at (317) 433 7140 (Eli Lilly and Company).

CONCLUSION

Applicants believe that the amendments they have made have placed the application in order for allowance.

Favorable consideration of the application is requested.

Respectfully submitted,



Hay, Martin Alexander

Agent for Applicants

Registration No. 39,459

Phone: 011 44 1625 500057

Email: martinahay@martin-a-hay.com

Customer No. 24330

[Martin A. Hay & Co.,

13 Queen Victoria Street

Macclesfield

Cheshire

SK11 6LP

UNITED KINGDOM]

January 8, 2009

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	
Filing Date	
First Named Inventor	Liebeschuetz, J. W.
Art Unit	
Examiner Name	
Attorney Docket Number	00219/US1

Sheet	1	of	5
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ² ~ Number ⁴ ~ Kind Code ⁵ (if known)				
	B1	WO 99/11657	03-11-1999	Proteus		
	B2	WO 99/11658	03-11-1999	Proteus		
	B3	WO 98/47876	10-29-1998	Akzo		
	B4	WO 00/76971	12-21-2000	Eli Lilly and Co		
	B5	WO 00/76970	12-21-2000	Eli Lilly and Co		
	B6	WO 00/77027	12-21-2000	Protherics		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	
Filing Date	
First Named Inventor	Liebeschuetz, J. W.
Art Unit	
Examiner Name	
Attorney Docket Number	00219/US1

Sheet	3	of	5
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	B13	WO 00/39111	07-06-2000	Eli Lilly and Co		
	B14	WO 00/39117	07-06-2000	Eli Lilly and Co		
	B15	WO 00/39118	07-06-2000	Eli Lilly and Co		
	B16	EP 796866A1	09-24-1997	Eli Lilly and Co		
	B17	WO 97/49404	12-31-1997	Eli Lilly and Co		
	B18	WO 00/71493	11-30-2000	Cor Therapeutics		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

C mplete if Known

(Use as many sheets as necessary)

Sheet	4	of	5
-------	---	----	---

Application Number	
Filing Date	
First Named Inventor	Liebeschuetz, J. W.
Art Unit	
Examiner Name	
Attorney Docket Number	00219/US1

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)				
	B19	WO 00/71507	11-30-2000	Cor Therapeutics		
	B20	WO 00/71508	11-30-2000	Cor Therapeutics		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Compleat if Known	
		Application Number	
		Filing Date	
		First Named Inventor	Liebeschuetz, J. W.
		Art Unit	
		Examiner Name	
Sheet 5	of 5	Attorney Docket Number	00219/US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Jones, Stuart D, et al., Bioorganic & Medicinal Chemistry Letters 11 (2001) 733-736	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.